Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) are exploring a key question in cancer immunotherapy: how to “wire” engineered natural killer (NK) cells so they respond faster and hit harder when they encounter…
SMARTWATCH screening has been shown to significantly improve atrial fibrillation detection in older, high-risk patients, with researchers reporting substantially higher diagnosis rates compared with standard care.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us